• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Who, what, and when-effective therapy for severe COVID-19.

作者信息

Kelmenson Daniel A, Cron Randy Q

机构信息

Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham Heersink School of Medicine, Birminham, AL 35233-1711, USA.

Division of Rheumatology, Department of Pediatrics, University of Alabama at Birmingham Heersink School of Medicine, Birminham, AL 35233-1711, USA.

出版信息

Lancet Rheumatol. 2022 Jan;4(1):e2-e3. doi: 10.1016/S2665-9913(21)00353-2. Epub 2021 Nov 17.

DOI:10.1016/S2665-9913(21)00353-2
PMID:34812425
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8598210/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/905f/8598210/d7370853c45e/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/905f/8598210/d7370853c45e/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/905f/8598210/d7370853c45e/fx1_lrg.jpg

相似文献

1
Who, what, and when-effective therapy for severe COVID-19.针对重症新型冠状病毒肺炎的有效治疗方法：适用人群、治疗手段及治疗时机
Lancet Rheumatol. 2022 Jan;4(1):e2-e3. doi: 10.1016/S2665-9913(21)00353-2. Epub 2021 Nov 17.
2
Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19.恩昔瑞韦对降低COVID-19高风险门诊患者严重结局的真实世界有效性
Infect Dis Ther. 2024 Aug;13(8):1821-1833. doi: 10.1007/s40121-024-01010-4. Epub 2024 Jun 28.
3
Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series - 465 Health Care Facilities, United States, December 2020-October 2021.≥18 岁完成初级 COVID-19 疫苗接种系列的人群中严重 COVID-19 结局的危险因素-465 家医疗保健机构，美国，2020 年 12 月-2021 年 10 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 7;71(1):19-25. doi: 10.15585/mmwr.mm7101a4.
4
Evaluating And Referring Patients For Outpatient Monoclonal Antibody Therapy For Coronavirus In The Emergency Department (Archived)在急诊科评估并转诊患者接受冠状病毒门诊单克隆抗体治疗（存档）
5
Monoclonal Antibody Therapy For High-Risk Coronavirus (COVID 19) Patients With Mild To Moderate Disease Presentations (Archived)针对轻度至中度症状的高危冠状病毒（COVID-19）患者的单克隆抗体疗法（存档）
6
Risk of Severe COVID-19 in Non-Adherent OSA Patients.未坚持治疗的阻塞性睡眠呼吸暂停患者发生重症新型冠状病毒肺炎的风险
Patient Prefer Adherence. 2022 Nov 9;16:3069-3079. doi: 10.2147/PPA.S387657. eCollection 2022.
7
Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.重症 COVID-19 患者恢复期血浆输血治疗——一项安全性、有效性和剂量反应研究：一项 II 期随机对照试验研究方案的结构化总结
Trials. 2020 Oct 26;21(1):883. doi: 10.1186/s13063-020-04734-z.
8
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.抗病毒联合治疗在新冠病毒感染有症状患者中的安全性和有效性 - 一项随机对照试验（SEV-COVID 试验）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 20;21(1):866. doi: 10.1186/s13063-020-04774-5.
9
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.英国风湿和肌肉骨骼疾病患者在利妥昔单抗治疗期间的严重急性呼吸综合征冠状病毒2突破性感染及中重度结局预测：一项单中心队列研究
Lancet Rheumatol. 2023 Feb;5(2):e88-e98. doi: 10.1016/S2665-9913(23)00004-8. Epub 2023 Jan 10.
10
Effectiveness of Corticosteroid Therapy for Non-Severe COVID-19 in Patients Not Requiring Supplemental Oxygen Who Have Risk Factors for Severe Disease.非重症 COVID-19 且无需补充氧气但有重症风险因素的患者使用皮质类固醇治疗的效果。
J Nippon Med Sch. 2022 Aug 27;89(4):422-427. doi: 10.1272/jnms.JNMS.2022_89-409. Epub 2022 Apr 11.

引用本文的文献

1
Hemophagocytic Lymphohistiocytosis Gene Variants in Severe COVID-19 Cytokine Storm Syndrome.重症 COVID-19 细胞因子风暴综合征中的噬血细胞性淋巴组织细胞增生症基因变异
Viruses. 2025 Aug 8;17(8):1093. doi: 10.3390/v17081093.
2
JAK Inhibitors in Cytokine Storm Syndromes.JAK 抑制剂在细胞因子风暴综合征中的应用。
Adv Exp Med Biol. 2024;1448:583-600. doi: 10.1007/978-3-031-59815-9_39.
3
IL-1 Family Blockade in Cytokine Storm Syndromes.白细胞介素-1 家族阻断在细胞因子风暴综合征中的应用。

本文引用的文献

1
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial.用于中重度新冠肺炎肺炎住院成人患者的萨瑞鲁单抗（CORIMUNO-SARI-1）：一项开放标签随机对照试验。
Lancet Rheumatol. 2022 Jan;4(1):e24-e32. doi: 10.1016/S2665-9913(21)00315-5. Epub 2021 Nov 17.
2
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.早期使用依那西普联合可溶性尿激酶型纤溶酶原激活物受体血浆水平指导 COVID-19 治疗：一项双盲、随机对照 3 期试验。
Nat Med. 2021 Oct;27(10):1752-1760. doi: 10.1038/s41591-021-01499-z. Epub 2021 Sep 3.
3
Adv Exp Med Biol. 2024;1448:553-563. doi: 10.1007/978-3-031-59815-9_36.
4
COVID-19 Pneumonia and Cytokine Storm Syndrome.新型冠状病毒肺炎及细胞因子风暴综合征
Adv Exp Med Biol. 2024;1448:307-319. doi: 10.1007/978-3-031-59815-9_22.
5
Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm.COVID-19 细胞因子风暴中阿那白滞素随机安慰剂对照试验中 IL-6 对生存的预测。
Viruses. 2023 Sep 30;15(10):2036. doi: 10.3390/v15102036.
6
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.COVID-19 患者中 JAK1/2 抑制剂芦可替尼引发的过度炎症：RuxCoFlam 试验。
Leukemia. 2023 Sep;37(9):1879-1886. doi: 10.1038/s41375-023-01979-w. Epub 2023 Jul 28.
7
Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients.免疫调节和血管内皮屏障保护介导了口服伊马替尼与住院 COVID-19 患者死亡率之间的关联。
Eur Respir J. 2022 Dec 15;60(6). doi: 10.1183/13993003.00780-2022. Print 2022 Dec.
8
No perfect therapy for the imperfect COVID-19 cytokine storm.对于并不完美的新冠病毒细胞因子风暴，没有完美的治疗方法。
Lancet Rheumatol. 2022 May;4(5):e308-e310. doi: 10.1016/S2665-9913(22)00068-6. Epub 2022 Mar 29.
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.
卡那奴单抗对比安慰剂对住院严重 COVID-19 患者免于有创机械通气的生存影响：一项随机临床试验。
JAMA. 2021 Jul 20;326(3):230-239. doi: 10.1001/jama.2021.9508.
4
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.COVID-19 住院患者中使用白细胞介素 6 拮抗剂与死亡率的关系：一项荟萃分析。
JAMA. 2021 Aug 10;326(6):499-518. doi: 10.1001/jama.2021.11330.
5
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia.托法替布治疗因 COVID-19 肺炎住院的患者。
N Engl J Med. 2021 Jul 29;385(5):406-415. doi: 10.1056/NEJMoa2101643. Epub 2021 Jun 16.
6
Defining the scourge of COVID-19 hyperinflammatory syndrome.定义新冠病毒超炎症综合征的危害
Lancet Rheumatol. 2020 Dec;2(12):e727-e729. doi: 10.1016/S2665-9913(20)30335-0. Epub 2020 Sep 29.
7
On the Alert for Cytokine Storm: Immunopathology in COVID-19.警惕细胞因子风暴：COVID-19 的免疫病理学。
Arthritis Rheumatol. 2020 Jul;72(7):1059-1063. doi: 10.1002/art.41285. Epub 2020 May 10.
8
Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era.综述：细胞因子风暴综合征：迈向精准医学时代
Arthritis Rheumatol. 2017 Jun;69(6):1135-1143. doi: 10.1002/art.40071.